Compare BEEM & PPCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BEEM | PPCB |
|---|---|---|
| Founded | 2006 | 2007 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Semiconductors | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.2M | 18.1M |
| IPO Year | 2018 | 2011 |
| Metric | BEEM | PPCB |
|---|---|---|
| Price | $0.69 | $1.71 |
| Analyst Decision | Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $2.50 | N/A |
| AVG Volume (30 Days) | ★ 593.3K | 125.5K |
| Earning Date | 11-24-2026 | 11-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 40.77 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $28,236,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $56.23 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.68 | $0.06 |
| 52 Week High | $2.31 | $6.79 |
| Indicator | BEEM | PPCB |
|---|---|---|
| Relative Strength Index (RSI) | 22.46 | 64.93 |
| Support Level | N/A | $1.23 |
| Resistance Level | $1.66 | $1.98 |
| Average True Range (ATR) | 0.05 | 0.22 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 8.30 | 58.82 |
Beam Global is a clean-technology innovation company. It develop, design, engineer, manufacture, and sell high-quality, renewably energized infrastructure products for electric vehicle ( EV ) charging, infrastructure for Smart Cities (the interconnected physical and digital elements within a city that utilize technology to enhance efficiency, sustainability, and quality of life for residents), energy security and disaster preparedness and energy-dense battery solutions in safe, compact and form-factors. Additionally, the company manufactures structures with electronic integration such as streetlighting, cell towers and energy infrastructure products as well as power electronics including invertors, charge controllers, power supplies and LED lighting.
Propanc Biopharma Inc is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer. The company develops a rational, composite formulation of the anti-cancer compound, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its product, PRP, is a variation upon its novel formulation and involves proenzymes, the inactive precursors of enzymes.